Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Osiris Therapeutics Inc

+ Add to Watchlist

OSIR:US

17.5200 USD 0.1400 0.81%

As of 20:10:00 ET on 03/03/2015.

Snapshot for Osiris Therapeutics Inc (OSIR)

Open: 17.5000 Day's Range: 17.1700 - 17.5500 Volume: 177,318
Previous Close: 17.3800 52wk Range: 11.8004 - 17.6900 1-Yr Rtn: +13.18%

Stock Chart for OSIR

No chart data available.
  • OSIR:US 17.5300
  • 1D
  • 1M
  • 1Y
17.3800
Interactive OSIR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OSIR

Current P/E Ratio (ttm) 298.6652
Estimated P/E(12/2014) 876.0000
Relative P/E vs. SPX 15.8879
Earnings Per Share (USD) (ttm) 0.0587
Est. EPS (USD) (12/2014) 0.0200
Est. PEG Ratio -
Market Cap (M USD) 601.29
Shares Outstanding (M) 34.32
30 Day Average Volume 96,637
Price/Book (mrq) 7.3225
Price/Sale (ttm) 12.3223
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OSIR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for OSIR

Osiris Therapeutics, Inc. researches and develops therapeutic products for the regeneration of human connective tissues. The Company is focusing its initial product development efforts on the regeneration of bone marrow stroma following high-dose cancer chemotherapy, and on the regeneration of bone in long bone and spinal defects.

Lode DebrabanderePresident/CEOPhilip R Jacoby JrCFO/Treasurer/Secretary
Jonathan M Hopper "Jon"Chief Medical OfficerFrank D Czworka JrVP/General Manager:Wound Care
More Company Profile & Key Executives for OSIR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil